Compare iShares Core High Dividend ETF (HDV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Twist Bioscience Corp — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and Twist Bioscience Corp is more actively traded (4,229,037 versus 2,925,562). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Twist Bioscience Corp for 27 Days on average.
| HDV | TWST | |
|---|---|---|
Market Cap | $14.68B | $10.08B |
Volume | 2,925,562 | 4,229,037 |
52-Week High | $29.93 | $205.00 |
52-Week Low | $23.64 | $25.45 |
Typical Hold Time | 117 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Current dividend yield is approximately 3% with recent quarterly payouts between $0.06-$0.10 per share. Technical indicators show RSI at 77.74 suggesting potential overbought conditions near-term.
The outlook remains positive given the ETF's sector rotation toward defensive holdings and income focus, though concentration risk has increased with 62% in three sectors. Key risks include interest rate sensitivity and sector concentration, while opportunities lie in defensive positioning during market volatility. The 3% yield provides income appeal but requires monitoring of sector allocations.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
